German entrepreneur and investor Christian Angermayer creates Atai Life Sciences and raises $25 million to study the therapeutic effects of psychedelic drugs on depression and other mental illnesses.
Christian Angermayer creates Atai Life Sciences to study the therapeutic effects of psychedelics on depression and other mental illnesses. So far he has raised $25 million from investors. Angermayer is already an investor in COMPASS Pathways and sees Atai focusing on financing similar research.
Psychedelic Science Review is working to bring cutting-edge science in the field of psychedelics to the public in the most accessible, thorough and accurate way possible. Join our communities on Facebook, Twitter, LinkedIn and Instagram and share our content with your network to help us bring scientifically-backed information about psychedelics to the world.
NEW! Shop the PSR Supporter Store to show your support for psychedelic science.